{"url_path":"/sec/kpti/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1503802/0001193125-26-222827-index.html","accession_number":"0001193125-26-222827","cik":"0001503802","ticker":"KPTI","issuer_name":"Karyopharm Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1503802/0001193125-26-222827-index.html","primary_entity_key":"0001503802","primary_entity_name":"Karyopharm Therapeutics Inc."},"word_count":375,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\n \n\n \n\n \n\n3.1\n\n \n\n[Restated Certificate of Incorporation of the Registrant, as amended](kpti-ex3_1.htm)\n\n \n\n \n\n \n\n4.1\n\n \n\n[Pre-Funded Warrant to Purchase Common Stock, dated March 26, 2026, by and between the Registrant and RA Capital Management.](kpti-ex4_1.htm)\n\n \n\n \n\n \n\n4.2\n\n \n\n[Warrant to Purchase Common Stock dated March 26, 2026, by and between the Registrant and RA Capital Management.](kpti-ex4_2.htm)\n\n \n\n \n\n \n\n10.1\n\n \n\n[Second Amendment to Credit and Guaranty Agreement, dated February 27, 2026 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the SEC on March 3, 2026).](https://www.sec.gov/Archives/edgar/data/1503802/000150380226000006/kpti-ex10_1.htm)\n\n \n\n \n\n \n\n10.2*\n\n \n\n[Securities Purchase Agreement, dated March 24, 2026, by and between the Company and RA Capital Management (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36167) filed with the SEC on March 24, 2026).](https://www.sec.gov/Archives/edgar/data/1503802/000119312526120770/d125009dex101.htm)\n\n \n\n \n\n \n\n10.3\n\n \n\n[Registration Rights Agreement, dated March 26, 2026, by and between the Company and RA Capital Management.](kpti-ex10_3.htm)\n\n \n\n \n\n \n\n31.1\n\n \n\n[Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.](kpti-ex31_1.htm)\n\n \n\n \n\n \n\n31.2\n\n \n\n[Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.](kpti-ex31_2.htm)\n\n \n\n \n\n \n\n32.1\n\n \n\n[Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](kpti-ex32_1.htm)\n\n \n\n \n\n \n\n32.2\n\n \n\n[Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](kpti-ex32_2.htm)\n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document.\n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)\n\n \n\n* Certain exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.\n\n82\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nKARYOPHARM THERAPEUTICS INC.\n\nDate: May 14, 2026\n\nBy:\n\n/s/ Richard Paulson\n\nRichard Paulson\n\nPresident and Chief Executive Officer\n\n(Principal executive officer)\n\nDate: May 14, 2026\n\nBy:\n\n/s/ Lori Macomber\n\nLori Macomber\n\nExecutive Vice President, Chief Financial Officer and Treasurer\n\n(Principal financial officer)\n\n \n\n \n\n83"}